Takara Bio Of Japan To Jointly Develop Liver Cancer Therapy With Chinese University
This article was originally published in PharmAsia News
Takara Bio announced Sept. 1 the company will jointly develop a liver cancer therapy with Zhongshan University Cancer Center in Guangzhou, China. Takara will combine its own immunotherapy with Zhongshan University's radio frequency therapy to kill cancer cells. The two parties plan to conduct the research on 30 patients in two years. According to Takara, immunotherapy combined with radio frequency therapy could lead to prevention of cancer recurrence. (Click here for more - Japanese language
You may also be interested in...
Fueled by a pipeline of more than 15 biosimilar candidates, Sandoz is aiming to treble the size of its $2bn global biosimilars business by 2030, targeting the US, Europe and Japan. Management spoke at length about the firm’s achievements and prospects during a meeting of parent Novartis’ management.
Rather than hitting the acquisition trial, Biogen has taken the licensing route to expand its psychiatric and neurological disorders pipeline.
After a stunning first efficacy readout for its mRNA-based vaccine, the biotech company's leaders in Europe talk about their rapid commercial and manufacturing scale-up.